title: Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension.
abstract: In this article, we review randomized controlled trials, open-label trials and pharmacoeconomic models of bosentan for the management of patients with pulmonary arterial hypertension. Bosentan consistently improves WHO functional class and quality of life, slows clinical worsening and is associated with improved survival compared with historical treatment. Although head-to-head trials are scarce, data directly comparing bosentan with sildenafil indicate no clinically significant differences between treatments as measured by the 6-min walk distance alone. Compared with historical care, bosentan treatment, over a 15-30-year period, increases the number of quality-adjusted life years (3.49 years). Economic modeling suggests that the cost-effectiveness of bosentan is similar to that of ambrisentan (US$43,725-57,778 per quality-adjusted life year), not as cost effective as sildenafil (at 20 mg three-times daily) and more cost effective than iloprost. More randomized controlled trials of longer duration are required to confirm the results from these economic models.
authors.affiliation: Monash University, Melbourne, VIC, Australia.
authors.forename: Geoff
authors.initials: G
authors.lastname: Strange
authors.forename: Anne
authors.initials: A
authors.lastname: Keogh
authors.forename: Brad
authors.initials: B
authors.lastname: Dalton
authors.forename: Eli
authors.initials: E
authors.lastname: Gabbay
mesh_terms: D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use*; D000077300:Bosentan; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000191:economics; D018803:Models, Economic; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use*; D013534:Survival; D016138:Walking
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan